Due to their complex mechanism of action and well-documented anti-inflammatory effects, GLP-1 analogues may constitute an important component of personalised therapy for the obesity-related asthma phenotype, which poses a therapeutic challenge for clinicians. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.